doi: 10.1016/j.abb.2015.11.032
Improve how your body handles insulin / blood sugar (very helpful in type 2 diabetes)
Editors Picks This week Novo Nordisk announced the launch of their weight-loss (GLP1) pill in the US
Use alarms or a calendar to keep track of dosing times Use a pillbox to ensure you take the right number of tablets each day Take your medicine during a routine, like brushing your teeth Check that you pack the right number of doses when traveling Additional tips for taking CALQUENCE: Take CALQUENCE as directed by your doctor
Supportive Research has found that grapefruit consumption is associated with a reduction in systolic blood pressure
Triple Agonists (GLP-1/GIP/Glucagon) Class Overview Monograph At a glance Prototype agent / retatrutide (LY3437943), Eli Lilly Mechanism / simultaneous GLP-1R, GIPR, and glucagon receptor co-agonism Phase 2 peak weight loss / up to 24.2% body weight at 48 weeks (retatrutide 12 mg) Primary indications in development / obesity, type 2 diabetes, MASLD/MASH, dyslipidemia Route and frequency / once-weekly subcutaneous injection Key differentiator from dual agonists / added glucagon receptor activity drives hepatic fat mobilization and energy expenditure Most common adverse effects / nausea, vomiting, diarrhea, constipation (dose-dependent) Regulatory status (as of mid-2025) / phase 3 trials ongoing
